Background: Red blood cell indices may add important prognostic information to risk stratification scores, such as Global Registry of Acute Coronary Events (GRACE) risk score. However, the incremental predictive value of red blood cell distribution width (RDW) on this score has not been assessed. Therefore, the aim of this study was to assess whether the RDW has additional prognostic value on the GRACE risk score in prediction of in-hospital mortality in patients with acute myocardial infarction (AMI).
Methods: A historic cohort was investigated at the University Hospital in Santa Maria city, Brazil. The laboratory database and medical registry were used to identify patients with AMI. A total of 109 patients were eligible for the present study. Cox regression models were calculated including GRACE risk score variables plus RDW. Moreover, measures of discrimination and calibration were also calculated. The primary outcome evaluated was all-cause in-hospital mortality.
Results: When included in a predictive model based on the GRACE risk score, RDW became an independent predictor of in-hospital mortality (HR 1.358, 95% CI 1.04 - 1.77; p = 0.023). The addition of RDW to the original model showed adequate calibration (Hosmer-Lemeshow p-value 0.174) and produced a slight improvement in its discriminatory power (AUC 0.769, 95% CI 0.677 - 0.847; p = < 0.0001).
Conclusions: We suggest that RDW might provide additional information over the GRACE risk score in patients with AMI.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.7754/clin.lab.2013.130907 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Integrating the GRACE Score with the Ceramide Risk Score Enhances the Predictive Accuracy of Major Adverse Cardiac Events in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention.
Rev Cardiovasc Med
January 2025
Department of Cardiology, Renmin Hospital of Wuhan University, 430060 Wuhan, Hubei, China.
Background: Ceramide, a key molecule in sphingolipid metabolism, is recognized as a standalone predictor of long-term major adverse cardiac events (MACE). We explore if integrating the global registry of acute coronary events (GRACE) score with the ceramide risk score (ceramide test 1, CERT1) improves MACE prediction in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI).
Methods: This cohort study included 210 participants with ACS undergoing PCI.
Clarification of factors associated with post-artesunate delayed hemolysis (PADH): analysis of 327 patients with severe imported Plasmodium falciparum malaria in France.
Travel Med Infect Dis
January 2025
Centre National de Référence du Paludisme, Paris, France; Centre de Recherche en Epidémiologie et Santé des Populations (CESP), INSERM U1018, Paris, France; Université Paris-Saclay, Service des Maladies infectieuses et tropicales, APHP, Hôpital Bicêtre, Le Kremlin-Bicêtre, France; Société Française de Médecine des Voyages.
Background: Post-Artesunate delayed hemolysis (PADH) occurs in approximately 15% of treated patients 2 to 3 weeks after artesunate administration. Identifying risk markers for PADH would help predict which patients are at higher risk.
Methods: In this prospective national cohort study conducted in a non-malaria endemic area from 2011 to 2016, a Cox proportional hazards model was used to assess the association between clinical and biological data available at Day 0 and the occurrence of PADH within 30 days of artesunate administration.
Long-Term Safety of Ixekizumab Treatment in Patients with Psoriasis, Psoriatic Arthritis, or Axial Spondyloarthritis: a Post Hoc Analysis of Cerebro-Cardiovascular Events.
Dermatol Ther (Heidelb)
January 2025
Blauvelt Consulting, LLC, Lake Oswego, OR, USA.
Introduction: Psoriasis (PsO), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA) may confer an increased risk for cardiovascular (CV) disease, including major adverse cerebro-cardiovascular events (MACE), deep vein thrombosis (DVT), and pulmonary embolism (PE). Patients with these conditions are often exposed for extended time periods to biologics, such as ixekizumab (IXE). Therefore, understanding the risk of CV events, especially MACE, in patients with PsO, PsA, and axSpA exposed to IXE is important.
View Article and Find Full Text PDFImplementing recommendations for routine mismatch repair (MMR) immunohistochemistry (IHC) testing of endometrial cancer and subsequent patient management.
BMJ Open Qual
January 2025
Gynaecological Oncology, GRACE Centre, Somerset NHS Foundation Trust, Taunton, UK
Lynch syndrome is associated with an increased risk of cancer, including endometrial cancer. We audited the introduction of a nurse-led testing and management pathway for Lynch syndrome. All 191 patients diagnosed with endometrial cancer at Somerset NHS Foundation Trust between January 2022 and December 2023 were tested for mis-match repair (MMR) protein immunohistochemistry; germline testing was offered to all 13 who were eligible.
View Article and Find Full Text PDFPrognostic impact of coronary microvascular dysfunction assessed by AMR in acute coronary syndrome patients with chronic kidney disease.
Front Cardiovasc Med
January 2025
Department of Cardiology, Peking University China-Japan Friendship School of Clinical Medicine, Beijing, China.
Background: Angiography-derived microcirculatory resistance (AMR) is proposed as a novel, pressure- temperature-wire-free and less-invasive method to evaluate coronary microvascular dysfunction (CMD). This study aims to examine the prognostic role of CMD assessed by AMR in predicting adverse events in acute coronary syndrome (ACS) patients with chronic kidney disease (CKD).
Methods: This retrospective cohort study included ACS with CKD patients in the China-Japan Friendship Hospital from January 2016 to November 2022.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!